19810-31-2 Usage
Chemical Properties
Colorless to yellow liquid
Uses
Different sources of media describe the Uses of 19810-31-2 differently. You can refer to the following data:
1. Benzyloxyacetyl chloride is a reagent used to construct substituted 2-azetidinones for further elaboration into annulated β-lactams. It is a commonly employed reagent for asymmetric synthesis of β-lactams. It is also used in preparation of (S)-3-(methylamino)-3-((R)-pyrrolidin-3-yl)propanenitrile, key intermediate in the preparation of fluoroquinolone antibiotic for respiratory tract infections, non-racemic helicene and β-lactams.
2. Commonly employed reagent for asymmetric synthesis of β-lactams.1,2
Check Digit Verification of cas no
The CAS Registry Mumber 19810-31-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,8,1 and 0 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 19810-31:
(7*1)+(6*9)+(5*8)+(4*1)+(3*0)+(2*3)+(1*1)=112
112 % 10 = 2
So 19810-31-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H9ClO2/c10-9(11)7-12-6-8-4-2-1-3-5-8/h1-5H,6-7H2
19810-31-2Relevant articles and documents
-
Fischer,Gohlke
, p. 1130,1138 (1933)
-
COMPOUNDS
-
Page/Page column 52; 76, (2021/12/08)
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS
-
Page/Page column 43; 44, (2020/07/07)
The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
